Feed CPRX
CP

Catalyst Pharmaceuticals

CPRX · NASDAQ

$31.49 -0.02% (-$0.01)
Market Cap $3.85B
P/E Ratio 17.42x
Div. Yield -
ROE 23.65%

Bulios Fair Price

$41.57

32.0% upside

Current Price

$31.49

Undervalued Fair Value Overvalued

According to Bulios Fair Price, CPRX is currently undervalued relative to its market price. How does it work?

Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?

Piotroski F-Score Moderate
4/9
Valuation
66 /100
Fair
EV/EBITDA 11.12x
P/S 6.46x
P/B 3.81x
Growth
100 /100
Growing
Rev. growth 40.10%
FCF growth 21.60%
Book val. growth 47.00%
Profitability
100 /100
Strong
Net margin 37.08%
Op. margin 44.83%
FCF margin 34.86%
Quality
91 /100
Excellent
ROE 23.65%
ROA 19.29%
Asset turnover 0.52x
Debt
100 /100
Low
Current ratio 7.10x
Net debt/EBITDA -2.70x
Debt/Equity 0.00x
Stability
50 /100
Moderate
Rev. volatility 37.15%
EPS volatility 62.81%
Profitable years 6

Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more

Ask StockBot about CPRX
Online

About the company

Catalyst Pharmaceuticals, Inc. (CPRX) is an American biopharmaceutical company specializing in research, development, and commercialization of drugs for rare neurological disorders. With activities in biotechnology and pharmacology, Catalyst Pharmaceuticals is a key player in the world of innovative treatment approaches. Their research focuses on discovering new treatment options and therapies for patients with neurological disorders, such as Lambert-Eaton myasthenic syndrome (LEMS). The company aims to provide modern treatment solutions and improve the quality of life for patients with rare diseases. Catalyst Pharmaceuticals is characterized by expertise in pharmacology and neurology. Catalyst Pharmaceuticals, Inc. (CPRX) shares could be suitable for investors looking for an investment opportunity in the biopharmaceutical sector with a company that specializes in innovative treatment approaches and therapies for patients with rare neurological disorders.

Sector

Healthcare

Industry

Biotechnology

CEO

Richard John Daly

Employees

182

Headquarters

Coral Gables

We use essential cookies to run the website and optional analytics cookies to measure usage. See our Privacy Policy.